Inovio Pharmaceuticals, Inc. (INO)

Market Cap	92.20M +29.7%
Revenue (ttm)	65,343 -70.0%
Net Income	-84.95M
EPS	-1.81
Shares Out	81.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,035,549
Open	1.150
Previous Close	1.130
Day's Range	1.110 - 1.150
52-Week Range	1.065 - 2.979
Beta	1.70
Analysts	Buy
Price Target	6.75 (+497.35%)
Earnings Date	May 12, 2026

About INO

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 12, 1998
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: INO
• Website: https://www.inovio.com

Financial Performance

In 2025, Inovio Pharmaceuticals's revenue was $65,343, a decrease of -69.99% compared to the previous year's $217,756. Losses were -$84.95 million, -20.80% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for INO stock is "Buy." The 12-month stock price target is $6.75, which is an increase of 497.35% from the latest price.

Price Target

$6.75

(497.35% upside)

Analyst Consensus: Buy